References
- [1] Bredy TW, Barad M. The histone deacetylase inhibitor valproic acid enhances acquisition, extinction, and reconsolidation of conditioned fear. Learn Mem. 2008; 15(1):39-45.10.1101/lm.801108
- [2] Heinrichs SC, Leite-Morris KA, Rasmusson AM, Kaplan GB. Repeated valproate treatment facilitates fear extinction under specific stimulus conditions. Neurosci Lett. 2013; 552:108-13.10.1016/j.neulet.2013.07.035
- [3] Hlavacova N, Jezova D. Chronic treatment with the mineralocorticoid hormone aldosterone results in increased anxiety-like behavior. Horm Behav. 2008; 54(1):90-7.10.1016/j.yhbeh.2008.02.004
- [4] Hlavacova N, Li Y, Pehrson A, Sanchez C, Bermudez I, Csanova A, Jezova D, Franklin M. Effects of vortioxetine on biomarkers associated with glutamatergic activity in an SSRI insensitive model of depression in female rats. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 82:332-338.10.1016/j.pnpbp.2017.07.008
- [5] Hlavacova N, Wes PD, Ondrejcakova M, Flynn ME, Poundstone PK, Babic S, Murck H, Jezova D. Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder. Int J Neuropsychopharmacol. 2012;15(2):247-65.10.1017/S1461145711000368
- [6] Lima IVA, Almeida-Santos AF, Ferreira-Vieira TH, Aguiar DC, Ribeiro FM, Campos AC, de Oliveira ACP. Antidepressant-like effect of valproic acid-Possible involvement of PI3K/Akt mTOR pathway. Behav Brain Res. 2017; 329:166-171.10.1016/j.bbr.2017.04.015
- [7] Pistovcakova J, Dostalek M, Sulcova A, Jezova D. Tiagabine treatment is associated with neurochemical, immune and behavioural alterations in the olfactory bulbectomized rat model of depression. Pharmacopsychiatry. 2008; 41(2):54-9.10.1055/s-2007-993212
- [8] Qiu HM, Yang JX, Jiang XH, Hu XY, Liu D, Zhou QX. Enhancing tyrosine hydroxylase and tryptophan hydroxylase expression and improving oxidative stress involved in the antidepressant effect of sodium valproate on rats undergoing chronic unpredicted stress. Neuroreport. 2015; 26(18):1145-50.10.1097/WNR.0000000000000482
- [9] Qiu HM, Yang JX, Liu D, Fei HZ, Hu XY, Zhou QX. Antidepressive effect of sodium valproate involving suppression of corticotropin-releasing factor expression and elevation of BDNF expression in rats exposed to chronic unpredicted stress. Neuroreport. 2014; 25(4):205-10.10.1097/WNR.0000000000000054
- [10] Smith LA, Cornelius VR, Azorin JM, Perugi G, Vieta E, Young AH, Bowden CL. Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord. 2010; 122(1-2):1-9.10.1016/j.jad.2009.10.033
- [11] Buzgoova K, Graban J, Balagova L, Hlavacova N, Jezova D. Brain derived neurotrophic factor expression and DNA methylation in response to subchronic valproic acid and/or aldosterone treatment. Croat Med J. 2019 (in press).10.3325/cmj.2019.60.71